Abstract
Objective To evaluate the therapeutic effect of intravitreal injection with bevacizumab (Avastin) (IVB)combined with extra-panretinal photocoagulation (E-PRP) for high-risk proliferative diabetic retinopathy (PDR). Methods A total of 57 eyes of 53 patients with high-risk PDR underwent intravitreal injection combined with E-PRP. The examinations of vision acuity, intraoeular pressure, iris fluorescein angiography (IFA), fundus photos and fundus fluorescein angiography (FFA) were performed on all of the patients before and 1, 2, 3, and 6 months after the treatment; the results of the examinations before and after the treatment were compared and analyzed. The average follow up was 6 months. Results The mean visual acuity was (0. 143 ± 0. 072) before the treatment and (0. 218 ± 0. 128) 7 days after the tretment; the difference was significant (t= -7. 940, P 0.05). The mean intraoeular pressure of 21 eyes which had the neovascularization of pupil margin and iris surface before and 7 days after IVB was (26. 632±2. 629) and (19. 316±3. 092) mm Hg (1 mm Hg=0. 133 kPa), respectively; the difference was significant (t=12. 838, P<0. 05) . The mean intraocular pressure 1, 3, and 6 months after E-PRP was (16. 947±2. 345), ( 16.474 ± 1.611 ), and (16. 421±4. 702 )mm Hg, respectively, which differed much from that before and after IVB (P<0. 05). Neovascularization on the disc and the retinae of 57 eyes were subsided partly, and a significant reduction or disappeared of the area of retinal neovascularization and the blood vessel leakage were observed 7 days after IVB. The neovascularization of pupil margin and iris surface of 21 eyes disappeared, and the IFA leakage decreased. The results of FFA 2 months after E-PRP showed that the one-off efficiency of E-PRP was 68.4%; 12 eyes (21.1%) needed an additional laser, in which 6 eyes (10.5 %) underwent vitreous surgery. Conclusion IVB combined with E-PRP as a treatment for high-risk PDR may improve the regression of retinal neovascularization and the reduction of vascular permeability, and prevent or reduce the complications and improve the therapeutic effect. Key words: Diabetic retinopathy/therapy; Laser coagulation/methods; Antibodies, monoclonal/drug effects
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
